ZBNA
RARE icon

Zions Bancorporation, National Association’s Ultragenyx Pharmaceutical RARE Stock Holding History

Zions Bancorporation, National Association’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.5K Buy
313
+49
+19% +$1.22K ﹤0.01% 901
2026
Q1 		$5.53K Buy
+264
New +$5.95K ﹤0.01% 978

Other funds holding RARE

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
FISPB
Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM
OAM
OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return

Zions Bancorporation, National Association's RARE Position: Q2 2026 in Review

Zions Bancorporation, National Association increased its Ultragenyx Pharmaceutical (RARE) stake by 19% in Q2 2026, buying an estimated $1.22K and bringing the position to 313 shares worth $10.5K. The position accounts for ﹤0.01% of the portfolio, ranked #901.

Zions Bancorporation, National Association first reported a position in RARE in Q1 2026 and has held it in 2 quarters since. 65 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Zions Bancorporation, National Association held 313 shares of Ultragenyx Pharmaceutical worth $10.5K as of Q2 2026.
  • Zions Bancorporation, National Association bought 49 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $1.22K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Zions Bancorporation, National Association's portfolio in Q2 2026, its #901 holding.
  • Zions Bancorporation, National Association first reported a position in Ultragenyx Pharmaceutical in Q1 2026 and has held it in 2 quarters since.
  • 65 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Zions Bancorporation, National Association's 13F filing for Q2 2026, filed 31 Jul 2026.